Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
May 21, 2018
Neuren announces investment and exclusive negotiation period
May 14, 2018
Notice of Annual General Meeting/Proxy Form
May 08, 2018
Appendix 4G
May 08, 2018
Annual Report to shareholders
Apr 30, 2018
Appendix 4C - quarterly
Apr 30, 2018
First patent in Japan granted for Neuren's trofinetide
Mar 29, 2018
Full Year Statutory Accounts
Mar 29, 2018
Disclosure under Listing Rule 4.3D
Feb 28, 2018
Preliminary Final Report
Jan 30, 2018
Appendix 4C - quarterly
Previous
1
2
3
4
